ArticleDiabetes2019
Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain.
Open access · bronzeAbstract read
In one paragraph
Article in Diabetes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 50 citations in OpenAlex.
- Selective deletion of FGFR1 in AgRP neurons impairs energy homeostasis under high-fat diet in mice.Molecular metabolism · 2026Article
- Sex-specific differences in mediobasal hypothalamus in response to nutritional states.Nature communications · 2026Article
- Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes.Molecular biomedicine · 2026Article
- Sustained diabetes remission induced by FGF1 involves a shift in transcriptionally distinct AgRP neuron subpopulations.Molecular metabolism · 2026Article
- Secreted proteins in treating metabolic dysfunction-associated steatotic liver disease: from bench towards bedside.Protein & cell · 2025Review
- A key role for parabrachial nucleus CGRP neurons in FGF1-Induced anorexia.Molecular metabolism · 2025Article
- AgRP neuron hyperactivity drives hyperglycemia in a mouse model of type 2 diabetes.The Journal of clinical investigation · 2025Article
- FGF-based drug discovery: advances and challenges.Nature reviews. Drug discovery · 2025Review
- The AMPK and AKT/GSK3β pathways are involved in recombinant proteins fibroblast growth factor 1 (rFGF1 and rFGF1a) improving glycolipid metabolism in rainbow trout (Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2024Article
- Review
- Brain Glucose Sensing and the Problem of Relative Hypoglycemia.Diabetes care · 2023Review
- Serum fibroblast growth factor 1 and its association with pancreatic beta cell function and insulin sensitivity in adults with glucose intolerance.Frontiers in endocrinology · 2023Article
- Autocrine FGF1 signaling promotes glucose uptake in adipocytes.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Sustained inhibition of NPY/AgRP neuronal activity by FGF1.JCI insight · 2022Article
- Combined micro-osmotic pump infusion and intracerebroventricular injection to study FGF1 signaling pathways in the mouse brain.STAR protocols · 2022Article
- Metabolic Messengers: fibroblast growth factor 1.Nature metabolism · 2022Review
- Stimulation of the hepatoportal nerve plexus with focused ultrasound restores glucose homoeostasis in diabetic mice, rats and swine.Nature biomedical engineering · 2022Article
- The ventromedial hypothalamic nucleus: watchdog of whole-body glucose homeostasis.Cell & bioscience · 2022Review
- Central Nervous System Control of Glucose Homeostasis: A Therapeutic Target for Type 2 Diabetes?Annual review of pharmacology and toxicology · 2022Review
- FGF1 and insulin control lipolysis by convergent pathways.Cell metabolism · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
17 authors at 5 institutions in 2 countries.
Jarrad M ScarlettUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, WA.ORCID 0000-0003-1019-346X
Kenjiro MutaUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, WA.
Jenny M BrownUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, WA.
Jennifer M RojasUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, WA.
Miles E MatsenUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, WA.
Nikhil K AcharyaUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, WA.
Anna SecherNovo Nordisk A/S, Måløv, Denmark.
Camilla IngvorsenNovo Nordisk A/S, Måløv, Denmark.
Rasmus JorgensenNovo Nordisk A/S, Måløv, Denmark.
Thomas Høeg-JensenNovo Nordisk A/S, Måløv, Denmark.
Darko StefanovskiNew Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA.
Richard N BergmanDiabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0003-1539-4471
Francesca PiccininiDiabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
Karl J KaiyalaDepartment of Oral Health Sciences, School of Dentistry, University of Washington, Seattle, WA.
Masakazu ShiotaDepartment of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN.
Gregory J MortonUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, WA.ORCID 0000-0002-8106-8386
Michael W SchwartzUniversity of Washington Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, WA mschwart@u.washington.edu.ORCID 0000-0003-1619-0331
University of Washington · USNovo Nordisk (Denmark) · DKCedars-Sinai Medical Center · USUniversity of Pennsylvania · USVanderbilt University · US
Funding
Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4MPILOT STUDY--CLINICAL NUTRITION RESEARCHP30DK035816 · NIDDK · UNIVERSITY OF WASHINGTON · PI GREGORY J MORTON · 1986 to 2026
$30.4MEXPERIMENTAL PATHOLOGY OF CARDIOVASCULAR DISEASET32HL007312 · NHLBI · UNIVERSITY OF WASHINGTON · PI MAJESKY, MARK W., SCHWARTZ, STEPHEN MARK · 1985 to 2019
$11.8MQUANTITATION OF FACTORS REGULATING GLUCOSE TOLERANCER01DK029867 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MARILYN ADER · 1986 to 2026
$11.0MDiabetes, Obesity and Metabolism Training ProgramT32DK007247 · NIDDK · UNIVERSITY OF WASHINGTON · PI GREGORY J MORTON, KRISTINA Marie UTZSCHNEIDER · 1986 to 2026
$10.0MNovel Brain Mechanisms Controlling Glucose HomeostasisR01DK083042 · NIDDK · UNIVERSITY OF WASHINGTON · PI SCHWARTZ, MICHAEL W · 2008 to 2025
$7.6MNutrition, Obesity and Atherosclerosis Training ProgramT32HL007028 · NHLBI · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1985 to 2026
$6.4MQUANTITATIVE STUDIES OF METABOLIC ORGAN DYNAMICSR01DK027619 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BERGMAN, RICHARD NATHAN · 1986 to 2022
$6.2MQuantitative Studies of Metabolic Organ DynamicsR37DK027619 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BERGMAN, RICHARD NATHAN · 2007 to 2016
$6.2MNeuroendocrine Control of Glucose MetabolismR01DK089056 · NIDDK · UNIVERSITY OF WASHINGTON · PI MORTON, GREGORY J · 2011 to 2024
$5.6MNovel Anti-Diabetic Actions of Hypothalamic FGF19-FGFR1 SignalingR01DK101997 · NIDDK · UNIVERSITY OF WASHINGTON · PI SCHWARTZ, MICHAEL W · 2014 to 2018
$1.9MCentral and Peripheral Mechanisms of FGF1-Mediated Remission of Diabetic HyperglycemiaK08DK114474 · NIDDK · UNIVERSITY OF WASHINGTON · PI SCARLETT, JARRAD M · 2017 to 2021
$813kNHLBI NIH HHS T32 HL007028NHLBI NIH HHS T32 HL007312NIDDK NIH HHS K08 DK114474NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK035816NIDDK NIH HHS R01 DK027619NIDDK NIH HHS R01 DK029867NIDDK NIH HHS R01 DK083042NIDDK NIH HHS R01 DK089056NIDDK NIH HHS R01 DK101997NIDDK NIH HHS R37 DK027619NIDDK NIH HHS T32 DK007247
Abstract
We recently reported that in rodent models of type 2 diabetes (T2D), a single intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1) induces remission of hyperglycemia that is sustained for weeks. To clarify the peripheral mechanisms underlying this effect, we used the Zucker diabetic fatty
Indexed as
AnimalsBlood GlucoseDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Fibroblast Growth Factor 1GlucokinaseGlucose Tolerance TestHumansHypoglycemic AgentsInsulinInsulin ResistanceMaleRatsRats, ZuckerReal-Time Polymerase Chain ReactionBlood GlucoseFibroblast Growth Factor 1GlucokinaseHypoglycemic AgentsInsulin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.